Business Context and Reporting Period
This Form 8-K Current Report was filed by Innoviva, Inc. on May 12, 2026, with the report signed on May 18, 2026. The filing primarily addresses changes to the Board of Directors under Item 5.02.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and director compensation.
Material Changes
- Resignations: On May 12, 2026, Directors Derek Small and Mark DiPaolo, Esq. resigned from the Board to focus on their roles at Syndeio BioSciences Inc., a company in which Innoviva has invested.
- Appointment: On May 18, 2026, the Board elected Josephine Linden as a new independent director. She is expected to serve on the Audit Committee.
- Compensation: Mrs. Linden received equity awards totaling approximately $331,250 in Restricted Stock Units (RSUs) and options to purchase 9,166 shares of common stock under the 2026 Equity Incentive Plan.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding Innoviva's growth strategy, capital deployment, and product commercialization. Key risks identified include:
- Potential lower-than-expected royalty revenue from respiratory products partnered with GSK.
- Commercialization challenges for products including RELVAR/BREO ELLIPTA, ANORO ELLIPTA, GIAPREZA, XERAVA, XACDURO, and NUZOLVENCE.
- Uncertainties regarding the timing of regulatory approvals and clinical study results.
- Risks related to the Company's growth strategy and capital return plans.
Management confirmed that the resignations of Messrs. Small and DiPaolo were not related to any disagreement with the Company regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the impact of the Board composition changes on the Audit Committee and overall governance.
- Review the latest Form 10-K or 10-Q for actual financial performance, as this 8-K contains no operational metrics.
- Monitor the commercialization progress of the listed respiratory and therapeutic products mentioned in the risk factors.
- Track the vesting schedule and potential dilution from the new equity awards granted to Director Linden.